T. Rowe Price Investment Management, Inc.

Position in ERAS — Erasca, Inc.

CIK 1897612 BALTIMORE, MD

Position in ERAS

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$388,124,570

+$44,143,498 QoQ

Shares Held

21,185,839

-0.3% QoQ

Ownership

6.06%

of shares outstanding

% of Portfolio

0.26%

of 13F equity value

Holder Rank

of 257 holders

Holding Since

Jun 2024

9 quarters on record

Voting authority Sole 97% Shared 0% None 3%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. ERAS ranks #10 (3.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc.	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc.	19,676,883	$416,953,150

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$388,124,570	21,185,839	-0.3%	Shares	Sole	2026-08-14
2026-03-31	$343,981,072	21,259,646	+344.1%	Shares	Sole	2026-05-15
2025-12-31	$17,806,989	4,786,825	-76.3%	Shares	Sole	2026-02-17
2025-09-30	$44,105,555	20,231,906	-0.5%	Shares	Sole	2025-11-14
2025-06-30	$25,821,844	20,332,161	+17.6%	Shares	Sole	2025-08-14
2025-03-31	$23,690,264	17,292,164	+3.5%	Shares	Sole	2025-05-14
2024-12-31	$41,942,970	16,710,347	-0.7%	Shares	Sole	2025-02-14
2024-09-30	$45,948,236	16,830,856	+128.2%	Shares	Sole	2024-11-14
2024-06-30	$17,403,487	7,374,359	—	Shares	Sole	2024-08-14
No filing history on record for this holder in this stock.